Skip to content

Study · Case report or series · n = 1 · 2023

8 results

Beneficial Effects of Setmelanotide in a 5-Year-Old Boy With POMC Deficiency and on His Caregivers.

Dubern B, Dubern B, Lourdelle A, Clément K

JCEM case reports1 May 2023Cited by 9 (Europe PMC)

PMID37908575 (opens in a new tab)PMCIDPMC10580505 (opens in a new tab)DOI10.1210/jcemcr/luad041 (opens in a new tab)PepBankPUB-37908575
Read at sourcePubMedAsk about this study
Jump to 8 results

Summary

The text of this summary is not shown here, because the article license does not allow reuse. Read it at the source (opens in a new tab)

Text rights: CC BY-NC-ND. Results still quote short attributed sentences.

Results from this study8

8 results from studies that gave the peptide. 8 results from people.

  1. 01HumanCase report or seriesEfficacy outcome

    In a boy with POMC deficiency, weight changed by -30 kg (-36%) from baseline during setmelanotide treatment.

    In plain wordsIn a boy with POMC deficiency, weight changed by -30 kg from baseline during setmelanotide treatment.

    Peptide
    Setmelanotide
    Outcome
    DecreaseBody weight
    Study

    n = 1

    Outcome group
    Body weight · Metabolic and weight
    Studied dose
    0.5 mg daily · 12 monthsAs given in this study (human).

    Measurements

    Body weight change from baseline
    −30 kg
    5-year-old boy with POMC deficiency, 12 months
    Body weight change from baseline
    −36%
    5-year-old boy with POMC deficiency, 12 months

    Source sentences

    Summary
    Daily administration of 0.5 mg setmelanotide for 12 months resulted in significant weight loss of -30 kg from baseline (-36% of weight loss) and improvements in hyperphagia and metabolic status.
    1 context sentence
    Summary · context
    Here, we describe the clinical benefit of setmelanotide administration in a 5-year-old child with severe hyperphagia and obesity due to POMC deficiency.
  2. 02HumanCase report or seriesEfficacy outcome

    In a boy with POMC deficiency, hyperphagia improved during setmelanotide treatment.

    In plain wordsIn a boy with POMC deficiency, excessive hunger improved during setmelanotide treatment.

    Peptide
    Setmelanotide
    Outcome
    DecreaseHyperphagia
    Study

    n = 1

    Outcome group
    Appetite and food intake · Metabolic and weight
    Studied dose
    0.5 mg daily · 12 monthsAs given in this study (human).

    Source sentences

    Summary
    Daily administration of 0.5 mg setmelanotide for 12 months resulted in significant weight loss of -30 kg from baseline (-36% of weight loss) and improvements in hyperphagia and metabolic status.
    1 context sentence
    Summary · context
    Here, we describe the clinical benefit of setmelanotide administration in a 5-year-old child with severe hyperphagia and obesity due to POMC deficiency.
  3. 03HumanCase report or seriesEfficacy outcome

    In a boy with POMC deficiency, metabolic status improved during setmelanotide treatment.

    In plain wordsIn a boy with POMC deficiency, metabolic health improved during setmelanotide treatment.

    Peptide
    Setmelanotide
    Outcome
    Direction not reportedMetabolic status
    Study

    n = 1

    Outcome group
    Metabolic Status · Metabolic and weight
    Studied dose
    0.5 mg daily · 12 monthsAs given in this study (human).

    Source sentences

    Summary
    Daily administration of 0.5 mg setmelanotide for 12 months resulted in significant weight loss of -30 kg from baseline (-36% of weight loss) and improvements in hyperphagia and metabolic status.
    1 context sentence
    Summary · context
    Here, we describe the clinical benefit of setmelanotide administration in a 5-year-old child with severe hyperphagia and obesity due to POMC deficiency.
  4. 04HumanCase report or seriesSafety outcome

    In a boy with POMC deficiency receiving setmelanotide, no major side effects were reported except hyperpigmentation and transient spontaneous erections.

    In plain wordsIn a boy receiving setmelanotide, no major side effects were reported except skin darkening and temporary spontaneous erections.

    Peptide
    Setmelanotide
    Outcome
    Not applicableMajor side effects
    Study

    n = 1

    Outcome group
    Adverse events · Whole body
    Studied dose
    0.5 mg daily · 12 monthsAs given in this study (human).

    Source sentences

    Summary
    No major side effects were observed, except for hyperpigmentation and transient spontaneous erections.
    1 context sentence
    Summary · context
    Here, we describe the clinical benefit of setmelanotide administration in a 5-year-old child with severe hyperphagia and obesity due to POMC deficiency.
  5. 05HumanCase report or seriesSafety outcome

    A boy with POMC deficiency developed hyperpigmentation during setmelanotide treatment.

    In plain wordsA boy with POMC deficiency had skin darkening during setmelanotide treatment.

    Peptide
    Setmelanotide
    Outcome
    Not applicableHyperpigmentation
    Study

    n = 1

    Outcome group
    Pigmentation · Skin and wound
    Studied dose
    0.5 mg daily · 12 monthsAs given in this study (human).

    Source sentences

    Summary
    No major side effects were observed, except for hyperpigmentation and transient spontaneous erections.
    1 context sentence
    Summary · context
    Here, we describe the clinical benefit of setmelanotide administration in a 5-year-old child with severe hyperphagia and obesity due to POMC deficiency.
  6. 06HumanCase report or seriesSafety outcome

    A boy with POMC deficiency had transient spontaneous erections during setmelanotide treatment.

    In plain wordsA boy with POMC deficiency had temporary spontaneous erections during setmelanotide treatment.

    Peptide
    Setmelanotide
    Outcome
    Not applicableTransient spontaneous erections
    Study

    n = 1

    Outcome group
    Adverse events · Reproductive and sexual health
    Studied dose
    0.5 mg daily · 12 monthsAs given in this study (human).

    Source sentences

    Summary
    No major side effects were observed, except for hyperpigmentation and transient spontaneous erections.
    1 context sentence
    Summary · context
    Here, we describe the clinical benefit of setmelanotide administration in a 5-year-old child with severe hyperphagia and obesity due to POMC deficiency.
  7. 07HumanCase report or seriesEfficacy outcome

    Clinical improvement during setmelanotide in a boy with POMC deficiency was associated with better parental quality of life.

    In plain wordsImprovement during setmelanotide in a boy with POMC deficiency was linked to better quality of life for his parents.

    Peptide
    Setmelanotide
    Outcome
    IncreaseParental quality of life
    Study

    n: not reported in source

    Outcome group
    Quality of life · Whole body
    Studied dose
    0.5 mg daily · 12 monthsAs given in this study (human).

    Source sentences

    Summary
    Interestingly, the clinical improvement of the child was associated with a remarkable improvement in the quality of life of the parents, along with a decrease in their emotional scores.
    1 context sentence
    Summary · context
    Here, we describe the clinical benefit of setmelanotide administration in a 5-year-old child with severe hyperphagia and obesity due to POMC deficiency.
  8. 08HumanCase report or seriesEfficacy outcome

    Clinical improvement during setmelanotide in a boy with POMC deficiency was associated with lower parental emotional scores.

    In plain wordsImprovement during setmelanotide in a boy with POMC deficiency was linked to lower emotional scores in his parents.

    Peptide
    Setmelanotide
    Outcome
    DecreaseParental emotional scores
    Study

    n: not reported in source

    Outcome group
    Anxiety and mood · Mental health and mood
    Studied dose
    0.5 mg daily · 12 monthsAs given in this study (human).

    Source sentences

    Summary
    Interestingly, the clinical improvement of the child was associated with a remarkable improvement in the quality of life of the parents, along with a decrease in their emotional scores.
    1 context sentence
    Summary · context
    Here, we describe the clinical benefit of setmelanotide administration in a 5-year-old child with severe hyperphagia and obesity due to POMC deficiency.

AI wrote and checked these results. AI can make mistakes, so check important results against the source.

Version history

PepBank keeps every version of the data on this study. Status changes from Retraction Watch, Europe PMC and Crossref are listed with their source.

  1. Version 2Current

    28 Oct 2026, 02:03 UTC

    Study results updated

  2. Version 1

    27 Oct 2026, 16:36 UTC

    First added · source update from Europe PMC

Subjects

Terms as the source lists them.

PepBank is a research reference. Talk to a doctor before you use any peptide.